AbbVie (NYSE: ABBV) today announced that late-breaking results from the Phase 2 IMGN853-0420 trial will be presented in an oral session at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting ...
A drug for a rare disease may extend the lives of ovarian cancer patients, a new trial has suggested. Patients with a certain ...
High levels of residential radon were linked to a roughly 30% higher risk for ovarian cancer in postmenopausal women, an ...
The data, presented during an oral plenary session at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting on ...
Investigators compared mortality risk among long-term survivors of high-grade serous ovarian cancer versus the general US population to examine how mortality and recurrence trends have changed with ...
Shares of Zentalis Pharmaceuticals rose after the company selected a higher dose of azenosertib to treat ovarian cancer in two clinical trials. The stock gained 49%, to $4.12, Thursday afternoon after ...
SAN JUAN, PUERTO RICO -- A novel regimen for platinum-resistant ovarian cancer solidified its role as a treatment option with ...
A drug typically used for a rare disorder could extend the lives of patients battling a form of ovarian cancer, a study has ...
A newly identified interaction between ovarian cancer cells and surrounding abdominal cells helps explain the cancer’s ...
Pharmaceutical Technology on MSN
MSD secures EC clearance for Keytruda combination therapy for ovarian cancer
The approval also covers Keytruda SC, known in the US as Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph).
Continuing a tradition in an effort to raise awareness and find a cure for ovarian cancer, the National Ovarian Cancer Coalition is hosting their annual Teal Lights cruise next month. Tickets are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results